An electrical & electronics engineer by qualification, Shikha Sinha has been working in the research and content domains for quite a while. Currently penning down informative pieces for page125.org, Shikha is also an active contributor on a variety of business portals spanning healthcare, ICT, renewables, etc. While she isn’t harnessing the power of the pen, Shikha loves to cook, read, and travel. She can be contacted at- [email protected] | https://twitter.com/shikhas999/
Renowned New York-based pharma magnate Pfizer Inc., has reportedly axed two trials of its Domagrozuma antibody. As per sources, the candidate development has been halted on the grounds of its disappointing failure to meet the required efficacy targets. For the uninitiated, the anti-myostatin antibody is …
AstraZeneca along with its global biologics research and development business, MedImmune, has reportedly announced that the phase III trial for anifrolumab has failed to meet its primary goal. As per trusted sources, the complete evaluation of the data is likely to be conducted after the …
